Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.540
-0.027 (-4.83%)
Nov 5, 2024, 1:11 PM EST - Market open
MTNB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | - | 1.1 | 3.19 | 0.03 | 0.16 | 0.09 | Upgrade
|
| Revenue Growth (YoY) | - | -65.62% | 9560.61% | -79.16% | 76.29% | -25.00% | Upgrade
|
| Cost of Revenue | 13.78 | 14.49 | 16.68 | 14.58 | 14.36 | 11.23 | Upgrade
|
| Gross Profit | -13.78 | -13.39 | -13.49 | -14.55 | -14.2 | -11.14 | Upgrade
|
| Selling, General & Admin | 9.99 | 10.37 | 11.1 | 10.19 | 10.01 | 7.78 | Upgrade
|
| Operating Expenses | 9.99 | 10.37 | 11.1 | 10.19 | 10.01 | 7.78 | Upgrade
|
| Operating Income | -23.76 | -23.77 | -24.59 | -24.74 | -24.21 | -18.92 | Upgrade
|
| Interest Expense | -0 | -0 | -0 | -0 | -0.01 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.85 | 0.83 | 3.59 | 1.46 | 1.76 | 1.56 | Upgrade
|
| EBT Excluding Unusual Items | -22.91 | -22.94 | -21 | -23.28 | -22.46 | -17.37 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.01 | - | Upgrade
|
| Pretax Income | -22.91 | -22.94 | -21 | -23.28 | -22.45 | -17.37 | Upgrade
|
| Net Income | -22.91 | -22.94 | -21 | -23.28 | -22.45 | -17.37 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 0.4 | 0.79 | 0.92 | Upgrade
|
| Net Income to Common | -22.91 | -22.94 | -21 | -23.68 | -23.24 | -18.3 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 4 | 4 | 4 | 4 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 4 | 4 | 4 | 4 | 3 | Upgrade
|
| Shares Change (YoY) | 3.80% | 0.21% | 3.16% | 6.75% | 35.61% | 48.00% | Upgrade
|
| EPS (Basic) | -5.08 | -5.28 | -4.84 | -5.63 | -5.90 | -6.30 | Upgrade
|
| EPS (Diluted) | -5.08 | -5.28 | -4.84 | -5.63 | -5.90 | -6.30 | Upgrade
|
| Free Cash Flow | -17.89 | -15.5 | -20.05 | -15.48 | -17.37 | -14.5 | Upgrade
|
| Free Cash Flow Per Share | -3.97 | -3.57 | -4.62 | -3.68 | -4.41 | -4.99 | Upgrade
|
| Operating Margin | - | -2168.43% | -771.33% | -74954.55% | -15288.38% | -21067.38% | Upgrade
|
| Profit Margin | - | -2093.25% | -658.63% | -71754.55% | -14678.10% | -20372.35% | Upgrade
|
| Free Cash Flow Margin | - | -1413.87% | -628.86% | -46918.18% | -10972.81% | -16142.24% | Upgrade
|
| EBITDA | -23.38 | -23.37 | -24.23 | -24.46 | -23.92 | -18.59 | Upgrade
|
| D&A For EBITDA | 0.39 | 0.39 | 0.36 | 0.28 | 0.29 | 0.33 | Upgrade
|
| EBIT | -23.76 | -23.77 | -24.59 | -24.74 | -24.21 | -18.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.